<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/C0E4FAD2-3C8B-410A-B6DF-3B9B9E433060"><gtr:id>C0E4FAD2-3C8B-410A-B6DF-3B9B9E433060</gtr:id><gtr:name>University of St Andrews</gtr:name><gtr:address><gtr:line1>College Gate</gtr:line1><gtr:line4>St. Andrews</gtr:line4><gtr:line5>Fife</gtr:line5><gtr:postCode>KY16 9AJ</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/2C711771-B8F6-4CDF-9AC3-9FAB317463D9"><gtr:id>2C711771-B8F6-4CDF-9AC3-9FAB317463D9</gtr:id><gtr:name>University of Cape Town</gtr:name><gtr:address><gtr:line1>Private Bag</gtr:line1><gtr:line2>Rondebosch</gtr:line2><gtr:postCode>7700</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>South Africa</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/DE956CB8-1DF4-49EB-BC34-78BD6095649A"><gtr:id>DE956CB8-1DF4-49EB-BC34-78BD6095649A</gtr:id><gtr:name>University of KwaZulu-Natal</gtr:name><gtr:address><gtr:line1>Govan Mbeki Centre</gtr:line1><gtr:line2>Westville Campus</gtr:line2><gtr:line3>Private Bag X54001</gtr:line3><gtr:postCode>4000</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/54F9413B-19F2-46DE-AFD4-245E4FB19B79"><gtr:id>54F9413B-19F2-46DE-AFD4-245E4FB19B79</gtr:id><gtr:name>Stellenbosch University</gtr:name><gtr:address><gtr:line1>Private Bag X1</gtr:line1><gtr:line2>19 Jonkershoek Road</gtr:line2><gtr:line3>Matieland</gtr:line3><gtr:region>Outside UK</gtr:region><gtr:country>South Africa</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/C0E4FAD2-3C8B-410A-B6DF-3B9B9E433060"><gtr:id>C0E4FAD2-3C8B-410A-B6DF-3B9B9E433060</gtr:id><gtr:name>University of St Andrews</gtr:name><gtr:department>Sch of Medicine</gtr:department><gtr:address><gtr:line1>College Gate</gtr:line1><gtr:line4>St. Andrews</gtr:line4><gtr:line5>Fife</gtr:line5><gtr:postCode>KY16 9AJ</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C0E4FAD2-3C8B-410A-B6DF-3B9B9E433060"><gtr:id>C0E4FAD2-3C8B-410A-B6DF-3B9B9E433060</gtr:id><gtr:name>University of St Andrews</gtr:name><gtr:address><gtr:line1>College Gate</gtr:line1><gtr:line4>St. Andrews</gtr:line4><gtr:line5>Fife</gtr:line5><gtr:postCode>KY16 9AJ</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2C711771-B8F6-4CDF-9AC3-9FAB317463D9"><gtr:id>2C711771-B8F6-4CDF-9AC3-9FAB317463D9</gtr:id><gtr:name>University of Cape Town</gtr:name><gtr:address><gtr:line1>Private Bag</gtr:line1><gtr:line2>Rondebosch</gtr:line2><gtr:postCode>7700</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>South Africa</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/DE956CB8-1DF4-49EB-BC34-78BD6095649A"><gtr:id>DE956CB8-1DF4-49EB-BC34-78BD6095649A</gtr:id><gtr:name>University of KwaZulu-Natal</gtr:name><gtr:address><gtr:line1>Govan Mbeki Centre</gtr:line1><gtr:line2>Westville Campus</gtr:line2><gtr:line3>Private Bag X54001</gtr:line3><gtr:postCode>4000</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/54F9413B-19F2-46DE-AFD4-245E4FB19B79"><gtr:id>54F9413B-19F2-46DE-AFD4-245E4FB19B79</gtr:id><gtr:name>Stellenbosch University</gtr:name><gtr:address><gtr:line1>Private Bag X1</gtr:line1><gtr:line2>19 Jonkershoek Road</gtr:line2><gtr:line3>Matieland</gtr:line3><gtr:region>Outside UK</gtr:region><gtr:country>South Africa</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/6CD959F1-84FE-486D-A904-62FA72C33862"><gtr:id>6CD959F1-84FE-486D-A904-62FA72C33862</gtr:id><gtr:firstName>Stephen</gtr:firstName><gtr:otherNames>Henry</gtr:otherNames><gtr:surname>Gillespie</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0601466"><gtr:id>6B9124A3-D3B2-4324-84E6-D6569A653F1B</gtr:id><gtr:title>Rapid Evaluation of Biomarkers in Tuberculosis</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0601466</gtr:grantReference><gtr:abstractText>Tuberculosis is a growing threat to human health throughout the world. If we are to reverse the increasing number of new cases and the rise of cases unable to be treated with the standard drugs we need new drugs and vaccines. The clinical studies in which drugs are tested are time consuming to perform because the treatment of tuberculosis takes a long time and patients may relapse for at least a year after they have finished their drugs. In addition large numbers of patients are required to provide a convincing result. 

In the past few years a number of new potential drugs for tuberculosis have been discovered and in order for these to be developed into medicines that can be used in the clinic soon it will be necessary to find new and quicker ways of testing them safely. A biomarker is a measure of a response to treatment which permits a reliable result to be predicted and this reduces the time taken to perform studies and the number of patients required in clinical trials. In this study we will use an international clinical study of tuberculosis treatment that we are performing to test potential biomarkers. These are different ways of measuring the burden of bacteria in the patient?s body and the patient?s immune response to the invading bacteria. Thus, we expect that this study will result in better ways to measure the response to treatment that will be used in all future clinical trials and will prove useful to health care workers treating tuberculosis across the world.</gtr:abstractText><gtr:technicalSummary>With the proliferation of potential new agents to be evaluated there is a pressing need to develop biomarkers that can shorten the time taken to trial new drugs and regimens. To date, the only accepted end point for tuberculosis clinical trials is bacteriological cure and absence of relapse at one year. This proposal explores clinically relevant and biologically significant biomarkers that predict the ability to render sputum culture negative and prevent relapse.

The international consortium making this proposal is responsible for a pivotal clinical trial evaluating the efficacy of moxifloxacin in tuberculosis treatment (REMoxTB - Rapid Evaluation of Moxifloxacin in Tuberculosis). This study, to be performed to international Good Clinical Practice and monitored by the Federal Drugs Administration will recruit up to 1500 patients and will follow them through treatment and for one year afterwards. Serial measures will be taken to evaluate the efficacy of two experimental regimens and the standard regimen. Thus, REMoxTB will provide an outstanding collection of well characterised clinical samples from a trial setting that will permit the comparison between the conventional measures of efficacy, bacteriological cure and relapse rate as well as several new approaches. We will collect sequential data on the bacterial load as measured by conventional bacteriological means. The delays associated with conventional culture methods will be addressed by using molecular methods; quantitative measurement of mRNA and transrenal DNA will be compared with the conventional measures of efficacy and modelling of bacterial load. We will also collect serial measures of the immune response to M. tuberculosis infection using ELISpot before during and after treatment. The REMoxTB study provides the ideal setting for the qualification of this promising, but yet not fully validated, T cell biomarker. An adaptation of our earlier non-linear model of bacteriological load measurement using a bi-exponential appraoch and the later application of non-linear mixed effects models recently proposed by Davies will be applied to analyse serial sputum culture colony counts. These methods are advantageous as they account for serial correlation and model the two phases of drug action separately.

This proposal evaluates the utility of several biomarkers in a clinical trials setting, providing the opportunity to inform the trials of the novel anti-tuberculous drugs entering the development pipeline.</gtr:technicalSummary><gtr:fund><gtr:end>2011-10-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2007-11-12</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>710936</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Cape Town</gtr:collaboratingOrganisation><gtr:country>South Africa, Republic of</gtr:country><gtr:department>Institute of Infectious Disease and Molecular Medicine (IIDMM)</gtr:department><gtr:description>Diagnosis of tuberculosis bacteria in paediatric stool</gtr:description><gtr:id>727AF091-56F7-4FA5-AA8C-D61AD48DB933</gtr:id><gtr:impact>ongoing work - no direct outputs yet</gtr:impact><gtr:outcomeId>F39jsV7iqEz-1</gtr:outcomeId><gtr:partnerContribution>UCR is collecting stool samples to test our recently published respiratory assay on.</gtr:partnerContribution><gtr:piContribution>We developed the assay which we will now modify and then test on the stool samples</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of KwaZulu-Natal</gtr:collaboratingOrganisation><gtr:country>South Africa, Republic of</gtr:country><gtr:description>Evaluation of methodology i</gtr:description><gtr:id>AEE93F0A-D2D8-4182-93C9-FBC52E8870A7</gtr:id><gtr:impact>Data from these studies have been presented informally and are being prepared for publication in international journals</gtr:impact><gtr:outcomeId>RNpBRtBtA7h-1</gtr:outcomeId><gtr:partnerContribution>Access to samples and access to specialist techniqes</gtr:partnerContribution><gtr:piContribution>This work had trialled methodology developed in this project in the field and to be a source of collection of immunological samples.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of St Andrews</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>School of Mathematics and Statistics St Andrews</gtr:department><gtr:description>Developing mathematical modelling</gtr:description><gtr:id>6A2C0C89-D7F9-4633-B0BD-2FC0EEEC1924</gtr:id><gtr:impact>Multidisciplinary collaboration. We have developed a new model that is being exploited in the main core of our research</gtr:impact><gtr:outcomeId>dmWZG4N719n-1</gtr:outcomeId><gtr:piContribution>Providing data to test mathematical models developed jointly</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medical Research Council (MRC)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC Clinical Trials Unit</gtr:department><gtr:description>Clinical Trials Unit</gtr:description><gtr:id>35D35948-AE05-40E0-9E26-B8CDE9693698</gtr:id><gtr:impact>Since the data is coming from a clinical trial for this part it hasn't yet been released</gtr:impact><gtr:outcomeId>49FA1C17A7B-1</gtr:outcomeId><gtr:partnerContribution>Statistical analysis for modeling of drug clearance of tuberculosis bacilli</gtr:partnerContribution><gtr:piContribution>We are providing the biological data for this analysis</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Stellenbosch</gtr:collaboratingOrganisation><gtr:country>South Africa, Republic of</gtr:country><gtr:description>Analysis of tuberculosis RNA in sputum</gtr:description><gtr:id>514F97CE-8FBC-4480-B385-22DB40483F09</gtr:id><gtr:impact>Use of the samples collected and stored at the University of Stellenbosch has allowed us to validate our newly developed enumeration assay. The data generated is currently being put together as a manuscript for publication</gtr:impact><gtr:outcomeId>2C90CF4A569-1</gtr:outcomeId><gtr:partnerContribution>provided longitudinal sputum samples from tuberculosis infected individuals</gtr:partnerContribution><gtr:piContribution>We applied our newly developed molecular based culture-free method to enumerate the number of tuberculosis bacilli in sputum samples provided by our collaborators.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Website entry</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>DFF2E052-E160-48AA-8B2E-787EAB20B0AD</gtr:id><gtr:impact>UCL website world TB day March 2009 http://www.ucl.ac.uk/news/news-articles/0903/09032402

N/A</gtr:impact><gtr:outcomeId>F994FA23C10</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>British Science Festival</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>939F7710-4A7B-475C-BAB0-9C128CB91AD7</gtr:id><gtr:impact>Invited lecture at the tuberculosis day of the British Science Festival Birmingham

None yet</gtr:impact><gtr:outcomeId>ZxkaNU5Bk7M</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>1000000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>PreDiCT-TB</gtr:description><gtr:end>2017-03-02</gtr:end><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:id>F0181029-F769-41DE-AF99-CB76ED7FDB42</gtr:id><gtr:outcomeId>q65E9YK2pD60</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2012-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>5902837</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>EU Innovative Medicines Initiative</gtr:description><gtr:end>2017-02-02</gtr:end><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:id>AC73775F-A60D-4A2E-9B1D-B7D8D3E70389</gtr:id><gtr:outcomeId>C8URvDu1YBN0</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2012-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>16500000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:department>European and Developing Countries Clinical Trials Partnership</gtr:department><gtr:description>Clinical trials call 2016</gtr:description><gtr:end>2022-02-02</gtr:end><gtr:fundingOrg>Sixth Framework Programme (FP6)</gtr:fundingOrg><gtr:id>28A3D36E-FD80-44FC-BE8A-14136BEFFAF1</gtr:id><gtr:outcomeId>58bfd2a3e7e226.96770445</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2017-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>176400</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>European Association of National Metrology Institutes (EURAMET)</gtr:description><gtr:end>2014-06-02</gtr:end><gtr:fundingOrg>European Association of National Metrology Institutes (EURAMET)</gtr:fundingOrg><gtr:id>0BB119E7-0068-4814-9AB1-11E7B860D2DC</gtr:id><gtr:outcomeId>k3m8exRYKGR</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-08-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>All Party Parliamentary Group for Tuberculosis Call for evidence</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>D8A06655-D50C-46C5-9293-7EC6DA82D9C7</gtr:id><gtr:outcomeId>Pje4YQmcKhj</gtr:outcomeId><gtr:type>Participation in a national consultation</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Stability and detection of DNA in urine samples was assessed. This was found to be variable and the results suggest that this would not represent a reliable biomarker for following response to tuberculosis treatment</gtr:description><gtr:id>E60B535A-8F53-4B05-9C92-30DC24A0EEAA</gtr:id><gtr:impact>These results were published as a paper in 2009</gtr:impact><gtr:outcomeId>8BDA5A1C696</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Analysis of trans-renal DNA</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2009</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>A molecular assay based on rRNA was developed to detect the number of bacteria in sputum. The method is related to a standard curve and inhibition and variable loss of RNA during sample processing detected by using a newly developed internal control based on a gene from potato. The method has been validated for 43 tuberculosis patients followed longitudinally. Currently the methods available require culture of organisms. Since tuberculosis bacteria are slow growing this requires substantial time delays. Techniques are also hampered by contamination of cultures with other organisms and loss of organisms due to decontamination procedures used to kill contaminants in order to prevent this. Additionally our new technique is sensitive enough to detect 100 bacteria in 1mL sputum which is an improvement compared to smear microscopy. The method is specific for tuberculosis complex bacteria and does not detect other mycobacteria.</gtr:description><gtr:id>93E080C6-7D97-45AD-9C43-DC9F17C03648</gtr:id><gtr:impact>N/A</gtr:impact><gtr:outcomeId>D1EDCB19DFD</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Rapid culture-free enumeration of tuberculosis bacilli in sputum</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>F1AD2815-E9E4-4F5D-8EC3-407C4DBD2890</gtr:id><gtr:title>The molecular bacterial load assay replaces solid culture for measuring early bactericidal response to antituberculosis treatment.</gtr:title><gtr:parentPublicationTitle>Journal of clinical microbiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/61bd037264be4879efa8c73ec0f96925"><gtr:id>61bd037264be4879efa8c73ec0f96925</gtr:id><gtr:otherNames>Honeyborne I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0095-1137</gtr:issn><gtr:outcomeId>56cacc8f535ac1.26571047</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6A034B5D-B833-482B-A939-AC78DF6F6C42</gtr:id><gtr:title>Radiological cavitation, sputum mycobacterial load and treatment response in pulmonary tuberculosis.</gtr:title><gtr:parentPublicationTitle>The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/723acb618989628fb0e91debea580ad8"><gtr:id>723acb618989628fb0e91debea580ad8</gtr:id><gtr:otherNames>Perrin FM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1027-3719</gtr:issn><gtr:outcomeId>McRnAqbVZ5x</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2AFFB960-619C-441F-B9E8-4F47F892C37B</gtr:id><gtr:title>Effective anti-tuberculosis therapy correlates with plasma small RNA.</gtr:title><gtr:parentPublicationTitle>The European respiratory journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/61bd037264be4879efa8c73ec0f96925"><gtr:id>61bd037264be4879efa8c73ec0f96925</gtr:id><gtr:otherNames>Honeyborne I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0903-1936</gtr:issn><gtr:outcomeId>5675e07607b84</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D64D0337-49D6-4E89-8C8C-FC2196B5A360</gtr:id><gtr:title>Strategies and challenges involved in the discovery of new chemical entities during early-stage tuberculosis drug discovery.</gtr:title><gtr:parentPublicationTitle>The Journal of infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/87629f27a2c658094b401add6b845f4f"><gtr:id>87629f27a2c658094b401add6b845f4f</gtr:id><gtr:otherNames>Coxon GD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0022-1899</gtr:issn><gtr:outcomeId>pm_12466_26_22448016</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CBA7972F-0D60-4FCB-8976-4A2131AF5B64</gtr:id><gtr:title>Implications of storing urinary DNA from different populations for molecular analyses.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3f1b3d60491591050b257b3d20e27124"><gtr:id>3f1b3d60491591050b257b3d20e27124</gtr:id><gtr:otherNames>Cannas A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>F97DE30363A</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>35F76563-F8B6-4D18-980F-712A5E416AA3</gtr:id><gtr:title>Profiling persistent tubercule bacilli from patient sputa during therapy predicts early drug efficacy.</gtr:title><gtr:parentPublicationTitle>BMC medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/61bd037264be4879efa8c73ec0f96925"><gtr:id>61bd037264be4879efa8c73ec0f96925</gtr:id><gtr:otherNames>Honeyborne I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1741-7015</gtr:issn><gtr:outcomeId>585d3c65c47df9.07721729</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>822E1246-78C2-4A69-B236-36C12F428104</gtr:id><gtr:title>Molecular bacterial load assay, a culture-free biomarker for rapid and accurate quantification of sputum Mycobacterium tuberculosis bacillary load during treatment.</gtr:title><gtr:parentPublicationTitle>Journal of clinical microbiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/61bd037264be4879efa8c73ec0f96925"><gtr:id>61bd037264be4879efa8c73ec0f96925</gtr:id><gtr:otherNames>Honeyborne I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0095-1137</gtr:issn><gtr:outcomeId>VBwrxTbEUxx</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5654B6D4-585F-45CE-A7EC-BF9361E120A3</gtr:id><gtr:title>Are patients on treatment for pulmonary TB who stop expectorating sputum genuinely culture negative?</gtr:title><gtr:parentPublicationTitle>Thorax</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/723acb618989628fb0e91debea580ad8"><gtr:id>723acb618989628fb0e91debea580ad8</gtr:id><gtr:otherNames>Perrin FM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0040-6376</gtr:issn><gtr:outcomeId>2EBA19AD8C5</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0FE12CEB-A3E5-481C-968C-6DBDFB0112C0</gtr:id><gtr:title>Innovative trial designs are practical solutions for improving the treatment of tuberculosis.</gtr:title><gtr:parentPublicationTitle>The Journal of infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2ea73e5c0a9951b8511cd9c8aec3c510"><gtr:id>2ea73e5c0a9951b8511cd9c8aec3c510</gtr:id><gtr:otherNames>Phillips PP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0022-1899</gtr:issn><gtr:outcomeId>pm_12466_26_22448027</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0601466</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CF950C9A-DB16-4E23-8AEB-94548777BCA1</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>1.1  Normal biological development and functioning</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>